Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD38+ Hematological Malignancies

NCT01084252 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01084252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01084252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD38+ Hematological Malignancies
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Completed
Start date
May 11, 2010
Completion date
July 13, 2023
Enrollment
351 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancy